Evidence map›Paper›PMID 36547387›Full record

ArticleImmunoHorizons2022

Acly Deficiency Enhances Myelopoiesis through Acetyl Coenzyme A and Metabolic-Epigenetic Cross-Talk.

Dalton L Greenwood, Haley E Ramsey, Phuong T T Nguyen, Andrew R Patterson, Kelsey Voss, Jackie E Bader, Ayaka Sugiura, Zachary A Bacigalupa, Samuel Schaefer, Xiang Ye and 6 more

Open access · goldAbstract read
In one paragraph

Article in ImmunoHorizons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Dalton L GreenwoodDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-0905-5211
Haley E RamseyDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Phuong T T NguyenDepartment of Cancer Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-6518-4849
Andrew R PattersonDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-5177-5055
Kelsey VossDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-1732-2682
Jackie E BaderDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.
Ayaka SugiuraDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.
Zachary A BacigalupaDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Samuel SchaeferDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-8175-1791
Xiang YeDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-8694-8710
Debolanle O DahunsiDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-5230-022X
Matthew Z MaddenDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-4062-4427
Kathryn E WellenDepartment of Cancer Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Michael R SavonaDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-3763-5504
P Brent FerrellDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-1140-9154
Jeffrey C RathmellDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-4106-3396
Vanderbilt University Medical Center · USCancer Research Institute · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
Exploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory diseaseR01DK105550 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey C Rathmell · 2015 to 2026
$4.7M
Metabolic Barriers to T Cell Activation in Clear Cell Renal Cell CarcinomaR01CA217987 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey C Rathmell · 2018 to 2026
$4.3M
Integrated Training in Engineering and DiabetesT32DK101003 · NIDDK · VANDERBILT UNIVERSITY · PI Jamey D. Young · 2014 to 2026
$3.9M
Targeting Tfh Cell Metabolic Regulation in SLE and SLE-Associated AtherosclerosisR01AI153167 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MAJOR, AMY S, RATHMELL, JEFFREY C. · 2020 to 2024
$2.8M
Acetyl-CoA metabolism and nutrient sensing in adipocytesR01DK116005 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI GUERTIN, DAVID A, WELLEN, KATHRYN ELAINE · 2019 to 2022
$2.0M
Investigating the role of the JAK/STAT3 Pathway in Clonal Proliferation and Immune Dysfunction in Myelodysplastic SyndromeK23HL138291 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FERRELL, PAUL B · 2017 to 2021
$817k
Targeting macrophages to reduce colorectal cancer: Impact of metabolic reprogrammingK00CA234920 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BADER, JACKIE · 2019 to 2022
$377k
Glycolysis and Glutaminase in CD8 T cell differentiation and anti-tumor immunityF30CA239367 · NCI · VANDERBILT UNIVERSITY · PI MADDEN, MATTHEW ZACHARY · 2020 to 2022
$130k
Connecting TCA cycle flux and epigenetic regulation of hematopoiesisF31HL152529 · NHLBI · VANDERBILT UNIVERSITY · PI GREENWOOD, DALTON LEE · 2020 to 2022
$90k
NCI NIH HHS F30 CA239367NCI NIH HHS K00 CA234920NCI NIH HHS R01 CA217987NHLBI NIH HHS F31 HL152529NHLBI NIH HHS K23 HL138291NIAID NIH HHS R01 AI153167NIDDK NIH HHS R01 DK105550NIDDK NIH HHS R01 DK116005NIDDK NIH HHS T32 DK101003NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM152284
6 · The paper itself

Abstract

Hematopoiesis integrates cytokine signaling, metabolism, and epigenetic modifications to regulate blood cell generation. These processes are linked, as metabolites provide essential substrates for epigenetic marks. In this study, we demonstrate that ATP citrate lyase (Acly), which metabolizes citrate to generate cytosolic acetyl-CoA and is of clinical interest, can regulate chromatin accessibility to limit myeloid differentiation. Acly was tested for a role in murine hematopoiesis by small-molecule inhibition or genetic deletion in lineage-depleted, c-Kit-enriched hematopoietic stem and progenitor cells from Mus musculus. Treatments increased the abundance of cell populations that expressed the myeloid integrin CD11b and other markers of myeloid differentiation. When single-cell RNA sequencing was performed, we found that Acly inhibitor-treated hematopoietic stem and progenitor cells exhibited greater gene expression signatures for macrophages and enrichment of these populations. Similarly, the single-cell assay for transposase-accessible chromatin sequencing showed increased chromatin accessibility at genes associated with myeloid differentiation, including CD11b, CD11c, and IRF8. Mechanistically, Acly deficiency altered chromatin accessibility and expression of multiple C/EBP family transcription factors known to regulate myeloid differentiation and cell metabolism, with increased Cebpe and decreased Cebpa and Cebpb. This effect of Acly deficiency was accompanied by altered mitochondrial metabolism with decreased mitochondrial polarization but increased mitochondrial content and production of reactive oxygen species. The bias to myeloid differentiation appeared due to insufficient generation of acetyl-CoA, as exogenous acetate to support alternate compensatory pathways to produce acetyl-CoA reversed this phenotype. Acly inhibition thus can promote myelopoiesis through deprivation of acetyl-CoA and altered histone acetylome to regulate C/EBP transcription factor family activity for myeloid differentiation.

Indexed as

ATP Citrate (pro-S)-LyaseChromatin Assembly and DisassemblyEpigenesis, GeneticMyelopoiesisAcetyl Coenzyme AAnimalsChromatinMiceAcetyl Coenzyme AATP Citrate (pro-S)-LyaseChromatin

Identifiers

PMID36547387
PMCPMC9935084
OpenAlexW4313455063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.